Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DNAJC10

Gene summary for DNAJC10

Gene summary.

Gene information	Species	Human
	Gene symbol	DNAJC10
	Gene ID	54431
	Gene name	DnaJ heat shock protein family (Hsp40) member C10
	Gene Alias	ERdj5
	Cytomap	2q32.1
	Gene Type	protein-coding
	GO ID	GO:0001932
	UniProtAcc	Q8IXB1

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
54431	DNAJC10	AEH-subject1	Human	Endometrium	AEH	1.27e-13	4.55e-01	-0.3059
54431	DNAJC10	AEH-subject3	Human	Endometrium	AEH	6.47e-31	6.99e-01	-0.2576
54431	DNAJC10	AEH-subject4	Human	Endometrium	AEH	1.65e-08	4.61e-01	-0.2657
54431	DNAJC10	EEC-subject1	Human	Endometrium	EEC	2.81e-08	3.26e-01	-0.2682
54431	DNAJC10	EEC-subject3	Human	Endometrium	EEC	4.20e-18	5.20e-02	-0.2525
54431	DNAJC10	EEC-subject4	Human	Endometrium	EEC	2.15e-14	4.45e-01	-0.2571
54431	DNAJC10	EEC-subject5	Human	Endometrium	EEC	7.27e-11	3.99e-01	-0.249
54431	DNAJC10	GSM5276934	Human	Endometrium	EEC	2.17e-10	-3.73e-01	-0.0913
54431	DNAJC10	GSM6177620_NYU_UCEC1_lib1_lib1	Human	Endometrium	EEC	1.47e-15	-2.24e-01	-0.1869
54431	DNAJC10	GSM6177620_NYU_UCEC1_lib2_lib2	Human	Endometrium	EEC	6.42e-24	-2.62e-01	-0.1875
54431	DNAJC10	GSM6177620_NYU_UCEC1_lib3_lib3	Human	Endometrium	EEC	1.66e-20	-6.63e-02	-0.1883
54431	DNAJC10	GSM6177621_NYU_UCEC2_lib1_lib1	Human	Endometrium	EEC	4.25e-15	8.91e-03	-0.1934
54431	DNAJC10	GSM6177622_NYU_UCEC3_lib1_lib1	Human	Endometrium	EEC	1.80e-32	-1.32e-02	-0.1917
54431	DNAJC10	GSM6177622_NYU_UCEC3_lib2_lib2	Human	Endometrium	EEC	1.41e-27	-9.20e-02	-0.1916
54431	DNAJC10	GSM6177623_NYU_UCEC3_Vis	Human	Endometrium	EEC	1.72e-15	4.55e-01	-0.1269
54431	DNAJC10	LZE2T	Human	Esophagus	ESCC	2.71e-03	3.09e-01	0.082
54431	DNAJC10	LZE4T	Human	Esophagus	ESCC	2.12e-06	1.74e-01	0.0811
54431	DNAJC10	LZE7T	Human	Esophagus	ESCC	1.55e-03	4.72e-01	0.0667
54431	DNAJC10	LZE8T	Human	Esophagus	ESCC	6.38e-05	1.27e-01	0.067
54431	DNAJC10	LZE24T	Human	Esophagus	ESCC	6.34e-09	2.91e-01	0.0596

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000193319	Oral cavity	OSCC	negative regulation of protein phosphorylation	191/7305	342/18723	1.58e-10	4.62e-09	191
GO:007005919	Oral cavity	OSCC	intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	47/7305	63/18723	9.85e-09	2.04e-07	47
GO:00327815	Oral cavity	OSCC	positive regulation of ATPase activity	18/7305	27/18723	3.34e-03	1.42e-02	18
GO:003497518	Oral cavity	OSCC	protein folding in endoplasmic reticulum	9/7305	11/18723	4.85e-03	1.92e-02	9
GO:00434626	Oral cavity	OSCC	regulation of ATPase activity	27/7305	46/18723	5.33e-03	2.07e-02	27
GO:009719334	Oral cavity	NEOLP	intrinsic apoptotic signaling pathway	79/2005	288/18723	1.41e-15	6.97e-13	79
GO:001049831	Oral cavity	NEOLP	proteasomal protein catabolic process	103/2005	490/18723	1.08e-11	1.65e-09	103
GO:004316131	Oral cavity	NEOLP	proteasome-mediated ubiquitin-dependent protein catabolic process	89/2005	412/18723	6.27e-11	7.44e-09	89
GO:004593633	Oral cavity	NEOLP	negative regulation of phosphate metabolic process	88/2005	441/18723	5.20e-09	2.87e-07	88
GO:001056333	Oral cavity	NEOLP	negative regulation of phosphorus metabolic process	88/2005	442/18723	5.82e-09	3.15e-07	88
GO:004232633	Oral cavity	NEOLP	negative regulation of phosphorylation	79/2005	385/18723	8.76e-09	4.48e-07	79
GO:000193332	Oral cavity	NEOLP	negative regulation of protein phosphorylation	70/2005	342/18723	6.77e-08	2.61e-06	70
GO:003497632	Oral cavity	NEOLP	response to endoplasmic reticulum stress	56/2005	256/18723	1.39e-07	4.84e-06	56
GO:000645732	Oral cavity	NEOLP	protein folding	45/2005	212/18723	5.31e-06	1.10e-04	45
GO:003497531	Oral cavity	NEOLP	protein folding in endoplasmic reticulum	7/2005	11/18723	3.57e-05	5.20e-04	7
GO:007005932	Oral cavity	NEOLP	intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	17/2005	63/18723	2.45e-04	2.54e-03	17
GO:009719318	Prostate	BPH	intrinsic apoptotic signaling pathway	110/3107	288/18723	7.36e-19	2.85e-16	110
GO:000645716	Prostate	BPH	protein folding	85/3107	212/18723	2.37e-16	4.74e-14	85
GO:001049818	Prostate	BPH	proteasomal protein catabolic process	153/3107	490/18723	4.13e-16	7.51e-14	153
GO:003497618	Prostate	BPH	response to endoplasmic reticulum stress	95/3107	256/18723	1.54e-15	2.52e-13	95

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0414126	Endometrium	AEH	Protein processing in endoplasmic reticulum	62/1197	174/8465	5.97e-13	1.39e-11	1.01e-11	62
hsa04141111	Endometrium	AEH	Protein processing in endoplasmic reticulum	62/1197	174/8465	5.97e-13	1.39e-11	1.01e-11	62
hsa0414127	Endometrium	EEC	Protein processing in endoplasmic reticulum	64/1237	174/8465	2.17e-13	5.09e-12	3.80e-12	64
hsa0414136	Endometrium	EEC	Protein processing in endoplasmic reticulum	64/1237	174/8465	2.17e-13	5.09e-12	3.80e-12	64
hsa04141211	Esophagus	ESCC	Protein processing in endoplasmic reticulum	147/4205	174/8465	3.29e-22	1.10e-19	5.64e-20	147
hsa04141310	Esophagus	ESCC	Protein processing in endoplasmic reticulum	147/4205	174/8465	3.29e-22	1.10e-19	5.64e-20	147
hsa0414114	Liver	Cirrhotic	Protein processing in endoplasmic reticulum	114/2530	174/8465	1.16e-22	9.67e-21	5.96e-21	114
hsa0414115	Liver	Cirrhotic	Protein processing in endoplasmic reticulum	114/2530	174/8465	1.16e-22	9.67e-21	5.96e-21	114
hsa0414122	Liver	HCC	Protein processing in endoplasmic reticulum	146/4020	174/8465	7.34e-24	2.46e-21	1.37e-21	146
hsa0414132	Liver	HCC	Protein processing in endoplasmic reticulum	146/4020	174/8465	7.34e-24	2.46e-21	1.37e-21	146
hsa0414130	Oral cavity	OSCC	Protein processing in endoplasmic reticulum	143/3704	174/8465	6.82e-26	2.28e-23	1.16e-23	143
hsa04141113	Oral cavity	OSCC	Protein processing in endoplasmic reticulum	143/3704	174/8465	6.82e-26	2.28e-23	1.16e-23	143
hsa0414162	Oral cavity	NEOLP	Protein processing in endoplasmic reticulum	49/1112	174/8465	9.02e-08	1.37e-06	8.59e-07	49
hsa0414172	Oral cavity	NEOLP	Protein processing in endoplasmic reticulum	49/1112	174/8465	9.02e-08	1.37e-06	8.59e-07	49
hsa0414128	Prostate	BPH	Protein processing in endoplasmic reticulum	97/1718	174/8465	2.37e-25	1.30e-23	8.07e-24	97
hsa04141112	Prostate	BPH	Protein processing in endoplasmic reticulum	97/1718	174/8465	2.37e-25	1.30e-23	8.07e-24	97
hsa0414129	Prostate	Tumor	Protein processing in endoplasmic reticulum	99/1791	174/8465	2.58e-25	1.71e-23	1.06e-23	99
hsa0414137	Prostate	Tumor	Protein processing in endoplasmic reticulum	99/1791	174/8465	2.58e-25	1.71e-23	1.06e-23	99

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DNAJC10

SNV

Missense_Mutation

rs371494397

c.1729N>A

p.Glu577Lys

p.E577K

Q8IXB1

protein_coding

deleterious(0.02)

benign(0.237)

TCGA-A2-A0CX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

DNAJC10

SNV

Missense_Mutation

c.1897N>A

p.Glu633Lys

p.E633K

Q8IXB1

protein_coding

tolerated(0.12)

possibly_damaging(0.805)

TCGA-A8-A0A7-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DNAJC10

SNV

Missense_Mutation

rs139539130

c.1897N>C

p.Glu633Gln

p.E633Q

Q8IXB1

protein_coding

tolerated(0.08)

possibly_damaging(0.903)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DNAJC10

SNV

Missense_Mutation

rs762911899

c.1253N>T

p.Pro418Leu

p.P418L

Q8IXB1

protein_coding

deleterious(0)

possibly_damaging(0.574)

TCGA-BH-A18Q-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DNAJC10

SNV

Missense_Mutation

novel

c.590N>A

p.Gly197Glu

p.G197E

Q8IXB1

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-EW-A6SA-01

Breast

breast invasive carcinoma

Male

<65

I/II

Unknown

DNAJC10

insertion

Frame_Shift_Ins

novel

c.1725_1726insAA

p.Asn576LysfsTer20

p.N576Kfs*20

Q8IXB1

protein_coding

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

DNAJC10

SNV

Missense_Mutation

rs768125706

c.2314G>A

p.Ala772Thr

p.A772T

Q8IXB1

protein_coding

tolerated(0.3)

benign(0.07)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

DNAJC10

SNV

Missense_Mutation

novel

c.1630N>A

p.Glu544Lys

p.E544K

Q8IXB1

protein_coding

tolerated(0.29)

benign(0.114)

TCGA-C5-A2LZ-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Unknown

DNAJC10

SNV

Missense_Mutation

rs141135661

c.316N>A

p.Asp106Asn

p.D106N

Q8IXB1

protein_coding

tolerated(0.07)

possibly_damaging(0.693)

TCGA-EK-A2RJ-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

DNAJC10

SNV

Missense_Mutation

rs776207150

c.356N>A

p.Arg119His

p.R119H

Q8IXB1

protein_coding

tolerated(0.06)

possibly_damaging(0.738)

TCGA-A6-2686-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1